London · Delayed Price · Currency is GBP · Price in USD BioNTech SE Statistics
Total Valuation
BioNTech SE has a market cap or net worth of GBP 17.26 billion. The enterprise value is 6.14 billion.
| Market Cap | 17.26B |
| Enterprise Value | 6.14B |
Important Dates
The last earnings date was Tuesday, August 4, 2026.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +3.00% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 16.35% |
| Owned by Institutions (%) | 19.89% |
| Float | 107.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.56 |
| PB Ratio | 1.13 |
| P/TBV Ratio | 1.26 |
| P/FCF Ratio | 42.71 |
| P/OCF Ratio | 29.48 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.74 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 15.19 |
Financial Position
The company has a current ratio of 7.85, with a Debt / Equity ratio of 0.02.
| Current Ratio | 7.85 |
| Quick Ratio | 7.03 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.67 |
| Interest Coverage | -127.06 |
Financial Efficiency
Return on equity (ROE) is -9.30% and return on invested capital (ROIC) is -36.69%.
| Return on Equity (ROE) | -9.30% |
| Return on Assets (ROA) | -5.41% |
| Return on Invested Capital (ROIC) | -36.69% |
| Return on Capital Employed (ROCE) | -9.88% |
| Weighted Average Cost of Capital (WACC) | 11.16% |
| Revenue Per Employee | 292,283 |
| Profits Per Employee | -186,002 |
| Employee Count | 7,807 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 3.74 |
Taxes
In the past 12 months, BioNTech SE has paid 49.00 million in taxes.
| Income Tax | 49.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -17.10% in the last 52 weeks. The beta is 1.28, so BioNTech SE's price volatility has been higher than the market average.
| Beta (5Y) | 1.28 |
| 52-Week Price Change | -17.10% |
| 50-Day Moving Average | 91.48 |
| 200-Day Moving Average | 97.81 |
| Relative Strength Index (RSI) | 50.19 |
| Average Volume (20 Days) | 2,795 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.59 |
Income Statement
In the last 12 months, BioNTech SE had revenue of GBP 2.28 billion and -1.45 billion in losses. Loss per share was -5.86.
| Revenue | 2.28B |
| Gross Profit | 1.75B |
| Operating Income | -1.56B |
| Pretax Income | -1.40B |
| Net Income | -1.45B |
| EBITDA | -1.19B |
| EBIT | -1.56B |
| Loss Per Share | -5.86 |
Balance Sheet
The company has 11.59 billion in cash and 272.19 million in debt, with a net cash position of 11.32 billion.
| Cash & Cash Equivalents | 11.59B |
| Total Debt | 272.19M |
| Net Cash | 11.32B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 15.29B |
| Book Value Per Share | 60.87 |
| Working Capital | 11.49B |
Cash Flow
In the last 12 months, operating cash flow was 585.27 million and capital expenditures -181.26 million, giving a free cash flow of 404.02 million.
| Operating Cash Flow | 585.27M |
| Capital Expenditures | -181.26M |
| Depreciation & Amortization | 372.73M |
| Net Borrowing | 19.91M |
| Free Cash Flow | 404.02M |
| FCF Per Share | n/a |
Margins
Gross margin is 76.62%, with operating and profit margins of -68.57% and -63.64%.
| Gross Margin | 76.62% |
| Operating Margin | -68.57% |
| Pretax Margin | -61.49% |
| Profit Margin | -63.64% |
| EBITDA Margin | -52.11% |
| EBIT Margin | -68.57% |
| FCF Margin | 17.84% |
Dividends & Yields
BioNTech SE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.00% |
| Shareholder Yield | -3.00% |
| Earnings Yield | -8.42% |
| FCF Yield | 2.34% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioNTech SE has an Altman Z-Score of 6.71 and a Piotroski F-Score of 2.
| Altman Z-Score | 6.71 |
| Piotroski F-Score | 2 |